- Home
- SANG vs IPHA Comparison
SANG vs IPHA Comparison
Compare SANG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- IPHA
- Stock Information
- Founded
- SANG 1984
- IPHA 1999
- Country
- SANG Canada
- IPHA France
- Employees
- SANG N/A
- IPHA N/A
- Industry
- SANG Computer Software: Programming Data Processing
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SANG Technology
- IPHA Health Care
- Exchange
- SANG Nasdaq
- IPHA Nasdaq
- Market Cap
- SANG 170.7M
- IPHA 187.0M
- IPO Year
- SANG 2021
- IPHA 2019
- Fundamental
- Price
- SANG $5.22
- IPHA $2.31
- Analyst Decision
- SANG Buy
- IPHA Strong Buy
- Analyst Count
- SANG 2
- IPHA 1
- Target Price
- SANG $5.63
- IPHA $11.50
- AVG Volume (30 Days)
- SANG 3.1K
- IPHA 5.5K
- Earning Date
- SANG 11-06-2024
- IPHA 09-12-2024
- Dividend Yield
- SANG N/A
- IPHA N/A
- EPS Growth
- SANG N/A
- IPHA N/A
- EPS
- SANG N/A
- IPHA N/A
- Revenue
- SANG $250,030,000.00
- IPHA $68,134,188.00
- Revenue This Year
- SANG N/A
- IPHA N/A
- Revenue Next Year
- SANG $3.05
- IPHA $105.84
- P/E Ratio
- SANG N/A
- IPHA N/A
- Revenue Growth
- SANG N/A
- IPHA 6.88
- 52 Week Low
- SANG $2.18
- IPHA $1.81
- 52 Week High
- SANG $6.40
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- SANG 49.22
- IPHA 53.25
- Support Level
- SANG $5.10
- IPHA $2.14
- Resistance Level
- SANG $5.64
- IPHA $2.35
- Average True Range (ATR)
- SANG 0.13
- IPHA 0.14
- MACD
- SANG -0.00
- IPHA 0.00
- Stochastic Oscillator
- SANG 30.00
- IPHA 61.76
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable Internet protocol communications systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes Cloud Services, Video Conferencing, Carrier Services, Business Phone Systems, Phones & Devices, and Network Connectivity. The company sells into three major geographic centers: the United States of America, which is the key revenue driver, Canada, and other foreign countries.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.